Beneficiaries need to meet at least one of the following, based on their BMI and health history when they first started GLP-1 therapy: A BMI of 35 or higher A BMI of 30 or higher, with a history of heart failure, uncontrolled hypertension, or chronic kidney disease A BMI of 27 or higher, with prediabetes, a previous heart attack or stroke, or symptomatic peripheral artery disease Beneficiaries who already have GLP-1 coverage under Part D for a separate condition, such as type 2 diabetes or sleep apnea, arent eligible for the Bridge
Available as an injectable or oral therapy, semaglutide helps curb appetite by emulating the natural hormone GLP-1, assisting adults in achieving significant weight loss
The 3-step in silico method described above can be utilized to determine the potential impact this modification can have on the HLA binding properties of the peptide
It is not designed to deliver the full therapeutic effect immediately
Our goal is to clarify their possible role in promoting healthy aging
Wu H, Lv B, Zhi L, Shao Y, Liu X, Mitteregger M, Chakaroun R, Tremaroli V, Hazen SL, Wang R, et al
